{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T13:07:46Z","timestamp":1789304866649,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0052655","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T22:39:16Z","timestamp":1356043156000},"page":"e52655","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies"],"prefix":"10.1371","volume":"7","author":[{"given":"Hema","family":"Dave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam R.","family":"Anver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna O.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Wayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivasubramanian","family":"Baskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Carroll WL, Bhojwani D, Min DJ, Raetz E, Relling M, <etal>et al<\/etal>.. (2003) Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program: 102\u2013131.","DOI":"10.1182\/asheducation-2003.1.102"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"CH Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12002","article-title":"The future role of monoclonal antibody therapy in childhood acute leukaemias","volume":"159","author":"M Barth","year":"2012","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study","volume":"26","author":"EA Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"JF Dijoseph","year":"2007","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, <etal>et al<\/etal>.. (2011) The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia.","DOI":"10.1038\/leu.2011.206"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"AS Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"MS Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"R Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","article-title":"A novel family of cell surface receptors with tyrosine kinase-like domain","volume":"267","author":"P Masiakowski","year":"1992","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"U Klein","year":"2001","journal-title":"J Exp Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"A Rosenwald","year":"2001","journal-title":"J Exp Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"S Baskar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"T Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"AH Daneshmanesh","year":"2008","journal-title":"Int J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL","volume":"29","author":"G Barna","year":"2011","journal-title":"Hematol Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"M Hudecek","year":"2010","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","author":"HE Broome","year":"2011","journal-title":"Leuk Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/10428190802124000","article-title":"Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms\u2019 tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia","volume":"49","author":"M Shabani","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1073\/pnas.0903233106","article-title":"RNAi screen for rapid therapeutic target identification in leukemia patients","volume":"106","author":"JW Tyner","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1182\/blood-2003-01-0338","article-title":"Classification of pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"102","author":"ME Ross","year":"2003","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"S Zhang","year":"2012","journal-title":"PLoS One"},{"key":"ref23","first-page":"517","article-title":"Validation of a multiplex RT-PCR assay for screening significant oncogene fusion transcripts in children with acute lymphoblastic leukaemia","volume":"44","author":"H Ariffin","year":"2003","journal-title":"Singapore Med J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/me.2011-1027","article-title":"Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor","volume":"26","author":"B Sanchez-Solana","year":"2012","journal-title":"Mol Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"J Yang","year":"2011","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"S Baskar","year":"2012","journal-title":"mAbs"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V76.1.117.117","article-title":"Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study","volume":"76","author":"WM Crist","year":"1990","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2443.1999.00234.x","article-title":"Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system","volume":"4","author":"I Oishi","year":"1999","journal-title":"Genes Cells"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s004270100140","article-title":"Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development","volume":"211","author":"R Al-Shawi","year":"2001","journal-title":"Dev Genes Evol"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Gashaw I (2011) What makes a good drug target? Drug Discovery Today 00.","DOI":"10.1016\/j.drudis.2011.12.008"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ncb1258","article-title":"Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance","volume":"7","author":"JP MacKeigan","year":"2005","journal-title":"Nat Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2\u20131\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"T Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","article-title":"Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis","volume":"71","author":"A Gentile","year":"2011","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2012.00034","article-title":"ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy","volume":"2","author":"G Rebagay","year":"2012","journal-title":"Front Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"R Lapalombella","year":"2010","journal-title":"Blood"},{"key":"ref36","first-page":"659","article-title":"Characterization of a myeloperoxidase mRNA(+) acute lymphoblastic leukemia cell line (EU-1\/ALL) established from a child with an apparent case of ALL","volume":"8","author":"M Zhou","year":"1994","journal-title":"Leukemia"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0052655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T03:25:22Z","timestamp":1643945122000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0052655"}},"subtitle":[],"editor":[{"given":"Ivan Cruz","family":"Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0052655","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}